Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled date : 2021 - 01 - 04 save search
Ampio Provides Update on Clinical Trials for Ampion™ Treatment of COVID-19 Patients
Published: 2021-01-04 (Crawled : 17:00) - biospace.com/
AMPE | $0.242 0.0% 15K
|
Health Technology
|
| O: 0.63%
H: 2.5%
C: -7.5%
covid trial treatment covid-19
HAWKINS ANNOUNCES IT HAS EXTENDED ITS WATER TREATMENT FOOTPRINT WITH ACQUISITIONS IN LOUISIANA
Published: 2021-01-04 (Crawled : 15:00) - globenewswire.com
HWKN 4 | $74.59 -0.15% -0.15% 360K
|
Distribution Services
|
| O: 1.13%
H: 0.49%
C: -1.89%
acquisition acquisitions treatment
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
Published: 2021-01-04 (Crawled : 15:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.47%
H: 0.66%
C: -0.58%
cancer therapy treatment application nivolumab
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma
Published: 2021-01-04 (Crawled : 15:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.47%
H: 0.66%
C: -0.58%
cancer therapy treatment application nivolumab
Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study
Published: 2021-01-04 (Crawled : 13:03) - globenewswire.com
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: 7.21%
H: 1.76%
C: -4.52%
treatment phase 2 phase 2/3
Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors
Published: 2021-01-04 (Crawled : 13:00) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: 3.13%
H: 17.16%
C: 13.54%
lung cancer cancer t-cell treatment
Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis
Published: 2021-01-04 (Crawled : 12:03) - globenewswire.com
PASG | $1.15 -4.17% -4.35% 280K
|
Health Technology
|
| O: 2.35%
H: 11.2%
C: 7.45%
gene therapy fda clearance fda therapy treatment gene therapies application clearance
Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency
Published: 2021-01-04 (Crawled : 11:03) - globenewswire.com
INZY | $4.5 -1.75% -1.78% 590K
|
Health Technology
|
| O: 4.26%
H: 11.85%
C: 8.6%
trial phase 3 phase 1 phase 2 treatment authorized
Gainers vs Losers
| 69% | 31% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
KNW 4 | $0.59 -0.71% 18.64% 27K
|
Manufacturing
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.